Decitabine for Injection

DRUG2 trials

Sponsors

Chen Suning, First Affiliated Hospital of Zhejiang University

Conditions

AML, AdultAcute Myeloid LeukemiaChemotherapy EffectMyelodysplastic Syndromes

Phase 2

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

RecruitingNCT06046313

First Affiliated Hospital of Zhejiang UniversityAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2023-10-19End: 2026-10-19Target: 120Updated: 2024-03-05

Phase 3

Venetoclax + Decitabine vs. 7+3 Induction Chemotherapy in Young AML

Active, not recruitingNCT05177731

Chen SuningAML, Adult, Chemotherapy Effect

Start: 2022-03-01End: 2024-12-31Updated: 2024-10-03

Related Papers

Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML

Blood2025-02-2625 citations

Venetoclax and Decitabine Compared with Standard Intensive Chemotherapy As Induction Therapy in Newly Diagnosed Acute Myeloid Leukemia: Updated Results of a Multicenter, Randomized, Phase 2b Trial

Blood2024-11-052 citations

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Blood2023-11-024 citations